Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Next Previous
Trial Profile

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Status: Recruiting
Phase of Trial: Phase 0

Latest Information Update: 19 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GT 801 (Primary)
  • Indications B-cell lymphoma; Haematological malignancies; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors GRIT Biotechnology

Most Recent Events

  • 06 Dec 2025 According to a Vivacta Bio media release, as of the November 30, 2025 data cutoff, two patients with non-Hodgkin's lymphoma have received multiple administrations of GT801 in the ongoing trial without lymphodepleting chemotherapy.
  • 06 Dec 2025 Results presented in a Vivacta Bio media release
  • 06 Dec 2025 According to a Vivacta Bio media release, initial data from the trial were presented in an oral session by Dr. Pin Wang, Chief Scientific Officer of Grit Biotherapeutics, at the 2025 American Society of Hematology (ASH) Annual Meeting in Orlando, Florida

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top